These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 11336434)
1. Pharmacological strategies for blood conservation in cardiac surgery: erythropoietin and antifibrinolytics. Hardy JF Can J Anaesth; 2001 Apr; 48(4 Suppl):S24-31. PubMed ID: 11336434 [TBL] [Abstract][Full Text] [Related]
2. Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial. Later AF; Maas JJ; Engbers FH; Versteegh MI; Bruggemans EF; Dion RA; Klautz RJ Eur J Cardiothorac Surg; 2009 Aug; 36(2):322-9. PubMed ID: 19250838 [TBL] [Abstract][Full Text] [Related]
3. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin. Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201 [TBL] [Abstract][Full Text] [Related]
4. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. ; Ferraris VA; Ferraris SP; Saha SP; Hessel EA; Haan CK; Royston BD; Bridges CR; Higgins RS; Despotis G; Brown JR; ; Spiess BD; Shore-Lesserson L; Stafford-Smith M; Mazer CD; Bennett-Guerrero E; Hill SE; Body S Ann Thorac Surg; 2007 May; 83(5 Suppl):S27-86. PubMed ID: 17462454 [TBL] [Abstract][Full Text] [Related]
5. Non-pharmacological strategies for blood conservation in cardiac surgery. Ruel MA; Rubens FD Can J Anaesth; 2001 Apr; 48(4 Suppl):S13-23. PubMed ID: 11336432 [TBL] [Abstract][Full Text] [Related]
6. Benefits and risks of aprotinin use during cardiac surgery. Kristeller JL; Roslund BP; Stahl RF Pharmacotherapy; 2008 Jan; 28(1):112-24. PubMed ID: 18154481 [TBL] [Abstract][Full Text] [Related]
7. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Brown JR; Birkmeyer NJ; O'Connor GT Circulation; 2007 Jun; 115(22):2801-13. PubMed ID: 17533182 [TBL] [Abstract][Full Text] [Related]
8. Aprotinin use in cardiac surgery patients at low risk for requiring blood transfusion. Kristeller JL; Stahl RF; Roslund BP; Roke-Thomas M Pharmacotherapy; 2007 Jul; 27(7):988-94. PubMed ID: 17594204 [TBL] [Abstract][Full Text] [Related]
9. Technologies to minimize blood transfusion in cardiac and orthopedic surgery. Results of a practice variation survey in nine countries. International Study of Peri-operative Transfusion (ISPOT) Investigators. Fergusson D; Blair A; Henry D; Hisashige A; Huet C; Koopman-van Gemert A; Katz E; McClelland B; Sigmund H; Laupacis A Int J Technol Assess Health Care; 1999; 15(4):717-28. PubMed ID: 10645113 [TBL] [Abstract][Full Text] [Related]
10. High-dose aprotinin, blood product transfusions, and short-term outcome in neonates and infants: a pediatric cardiac surgery center experience. Bojan M; Boulat C; Peperstraete H; Pouard P Paediatr Anaesth; 2012 Aug; 22(8):818-25. PubMed ID: 22416677 [TBL] [Abstract][Full Text] [Related]
11. Evaluation and management of bleeding during cardiac surgery. Levy JH; Tanaka KA; Steiner ME Curr Hematol Rep; 2005 Sep; 4(5):368-72. PubMed ID: 16131437 [TBL] [Abstract][Full Text] [Related]
12. Antifibrinolytics in cardiac surgery. Dhir A Ann Card Anaesth; 2013; 16(2):117-25. PubMed ID: 23545866 [TBL] [Abstract][Full Text] [Related]
13. Current antifibrinolytic therapy for coronary artery revascularization. Trudell J; McMurdy N AANA J; 2008 Apr; 76(2):121-4. PubMed ID: 18478817 [TBL] [Abstract][Full Text] [Related]
14. Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or a combination? Bulutcu FS; Ozbek U; Polat B; Yalçin Y; Karaci AR; Bayindir O Paediatr Anaesth; 2005 Jan; 15(1):41-6. PubMed ID: 15649162 [TBL] [Abstract][Full Text] [Related]
15. Living without aprotinin: the results of a 5-year blood saving program in cardiac surgery. Ranucci M; Castelvecchio S; Romitti F; Isgrò G; Ballotta A; Conti D Acta Anaesthesiol Scand; 2009 May; 53(5):573-80. PubMed ID: 19173686 [TBL] [Abstract][Full Text] [Related]
16. Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a meta-analysis of epidemiologic studies. Gagne JJ; Griesdale DE; Schneeweiss S Pharmacoepidemiol Drug Saf; 2009 Apr; 18(4):259-68. PubMed ID: 19185048 [TBL] [Abstract][Full Text] [Related]
17. Natural and synthetic antifibrinolytics in adult cardiac surgery: efficacy, effectiveness and efficiency. Hardy JF; Bélisle S Can J Anaesth; 1994 Nov; 41(11):1104-12. PubMed ID: 7530172 [TBL] [Abstract][Full Text] [Related]
18. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Karkouti K; Beattie WS; Dattilo KM; McCluskey SA; Ghannam M; Hamdy A; Wijeysundera DN; Fedorko L; Yau TM Transfusion; 2006 Mar; 46(3):327-38. PubMed ID: 16533273 [TBL] [Abstract][Full Text] [Related]